{"cdcTestId":"2022-0076","testcaseName":"Patient is administered the second dose of Moderna Covid-19 Vaccine at 28 - 4 days and a bivalent booster as the third dose","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Not Recommended: series complete","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"1957-07-19T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Complete","administeredDoses":[{"dateAdministered":"2022-07-19T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-08-12T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-12T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"229","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"","earliestDate":"0001-01-01T00:00:00","recommendedDate":"0001-01-01T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-07-19T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-08-12T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-12T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"229","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T11:52:05.709","generalDescription":"This test case describes when a patient is administered a second dose of the Covid-19 vaccine (Moderna) at 28-4 days after the first dose, and a third dose as Moderna\u0027s bivalent booster dose, that the doses are valid.  Series is complete.","changedInVersion":"4.27","reasonForChange":"v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.\nv4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 18 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).\nv4.13 - Updated test case to include the forecasting of a booster dose, at an interval of 6 months from most recent dose, for individuals 65 years and older who have completed a primary series."}